A summary is provided of Sumitomo Pharma’s share price movements, including nighttime PTS trading, and its financial results for the first quarter of the fiscal year ending March 2027. Revenue increased, while operating profit declined and profit attributable to owners of parent rose sharply.
Sumitomo Pharma’s nighttime PTS quoted price was ¥1,612 (17:44), down ¥1.5, or 0.09%, from the TSE closing price. Data on the nighttime trading price, trading volume and trading value is also provided for the latest trading activity.
According to the summary of the financial results report, revenue for the first quarter of the fiscal year ending March 2027 rose 19.9% year on year to ¥129.5 billion, while operating profit fell 10.8% to ¥18.2 billion, partly due to the impact of the transfer of an equity interest in the Asian business and higher expenses. Meanwhile, profit attributable to owners of parent rose 51.7% to ¥17.0 billion.
Future performance checkpoints include expanding sales of core products in the United States, switching products in the Japanese market, progress in clinical trials in oncology, commercialisation of regenerative and cellular medicines, and securing investment capacity through a capital increase. Risks identified include changes in the product mix, higher promotional and research and development expenses, foreign exchange movements, and supply-chain risks.
The next financial results announcement is scheduled for around late October 2026. Historical performance trends indicate improvement in terms of profitability, stability and growth.